Myriad Genetics Inc (NAS:MYGN)
$ 24.225 -1.735 (-6.68%) Market Cap: 2.20 Bil Enterprise Value: 2.40 Bil PE Ratio: 0 PB Ratio: 2.97 GF Score: 79/100

Q4 2021 Myriad Genetics Inc Earnings Call Transcript

Feb 24, 2022 / 09:30PM GMT
Release Date Price: $25.47 (+7.02%)
Operator

Greetings, and welcome to the Myriad Genetics Fourth Quarter 2021 Financial Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded Thursday, February 24, 2022.

I would now like to turn the conference over to Nathan Smith, Senior Vice President of Investor Relations. Please go ahead.

Nathan Smith
Myriad Genetics, Inc. - SVP of IR & Treasury

Thank you, Kevin. Good afternoon, and welcome to the Myriad Genetics Fourth Quarter 2021 Earnings Call. During the call, we will review the financial results we released today, and afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this morning on Form 8-K and can be found on our website at investor.myriad.com.

I'm Nathan Smith, the Senior Vice President of Investor Relations, and on the call today with me are Paul Diaz, our President and Chief Executive Officer; Bryan Riggsbee, our Chief Financial Officer; and Nicole Lambert, our Chief Operating Officer.

This call can be heard live via webcast at investor.myriad

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot